8. Cogent Biosciences Inc. (NASDAQ:COGT)
Number of Hedge Fund Holders — 75
Bezuclastinib Approaches Decisions That Could Reshape the Business
Cogent Biosciences, Inc. (NASDAQ: COGT) is approaching a period in which regulatory decisions could materially change its position among cancer drug developers. The FDA assigned a November 30, 2026 target action date to its application for bezuclastinib combined with sunitinib in gastrointestinal stromal tumors following prior imatinib treatment. The application received Priority Review, supported by the Phase 3 PEAK study. In that trial, median progression-free survival reached 16.5 months with the combination, compared with 9.2 months for sunitinib alone. The hazard ratio of 0.50 indicates a substantial reduction in the risk of progression or death during the study.
The development program extends beyond that oncology application. In its August business update, management identified a December 30, 2026 target action date for bezuclastinib in nonadvanced systemic mastocytosis and confirmed submission of a separate application in advanced systemic mastocytosis. Chief Executive Officer Andrew Robbins described “transformative milestones” following three applications supported by positive pivotal studies. These are distinct disease settings, however, and their commercial prospects should be evaluated separately. A successful review in one indication would not automatically settle questions about approval, labeling, or uptake in another. The regulatory calendar is busy, but each appointment still requires its own outcome.
Commercial preparation is already underway. The company reported completion of onboarding for its customer-facing commercial and medical teams, alongside a pro forma cash balance of $865.9 million that management expected to support operations into late 2028. For investors researching targeted cancer therapy stocks, that combination of late-stage evidence and launch preparation is significant. The next test is execution: obtaining approval where sought, explaining the treatment’s clinical role to physicians, securing reimbursement, and converting patient demand into sustainable revenue. Hiring a sales team demonstrates readiness; it does not guarantee that prescriptions will follow at the pace embedded in the share price.
Ranking rationale — Cogent Biosciences, Inc. (NASDAQ: COGT) ranks eighth with 75 hedge fund holders. Positive pivotal evidence and approaching regulatory milestones support its inclusion, while approval outcomes, launch spending, and the absence of an established commercial franchise remain important investment risks.
